Acorda Sets Ampyra Price Above Estimates, Reaps Benefit Of Clean Labeling
Highlighting the upside of receiving clean labeling from FDA, Acorda set the price for its multiple sclerosis drug Ampyra higher than the company had originally projected - at nearly $13,000/year per patient
You may also be interested in...
Acorda's challenge in marketing its multiple sclerosis drug Ampyra is not that it is a new drug, but that it is a new drug indicated to treat an aspect of the disease that has never before been treated
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials